AstraZeneca Still Aiming for Oxford Covid Vaccine by Year-End, CEO Says
- CEO Soriot seeks to reassure investors after trial halt
- Trial participant’s diagnosis is still not certain, chief says
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
AstraZeneca Plc Chief Executive Officer Pascal Soriot said the coronavirus vaccine the company is developing with the University of Oxford could still be ready before the end of the year after pausing its trials due to a possible serious neurological problem in one participant.